Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Tesla Raises Cybertruck Prices by $5,000 in US 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
3 clinical-grade skincare creams you really shouldn’t buy online 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Add as a preferred source on Google
Novo Nordisk (CSE: NOVOb, NYSE: NVO) raised its full-year 2025 guidance after stronger-than-expected demand for its blockbuster weight-loss drugs helped improve its earnings outlook. The Danish pharmaceutical company now expects annual sales and operating profit to decline by no more than 6% at constant exchange rates, an improvement from its previous forecast of a 4% to 12% decline.
Despite the upgraded outlook, Novo Nordisk shares fell sharply as investors reacted to weaker-than-expected sales of the new oral version of Wegovy and disappointing clinical trial results for its experimental obesity treatment, CagriSema. U.S.-listed shares dropped about 6% on Tuesday, while Copenhagen-listed stock declined more than 4% in early Wednesday trading.
During the second quarter, oral Wegovy generated sales of 3.2 billion Danish kroner (around $500 million), slightly below analysts’ expectations of 3.3 billion kroner. Meanwhile, the injectable version of Wegovy remained the company’s top performer, delivering 19.48 billion kroner in quarterly revenue.
Investor sentiment was also pressured by new trial data showing CagriSema lagged Eli Lilly’s tirzepatide in blood sugar control among patients with Type 2 diabetes. While CagriSema met the primary goal of demonstrating noninferior weight loss, with patients losing an average of 15.2% of body weight compared with 15.8% for tirzepatide, it failed to match its rival in reducing HbA1c levels. CagriSema lowered HbA1c by 1.9%, versus 2.2% achieved by tirzepatide.
Market analysts noted the results were weaker than expected, particularly because Novo Nordisk had aimed to demonstrate noninferiority across both primary endpoints. The outcome strengthens Eli Lilly’s competitive position in the rapidly expanding obesity and diabetes treatment market.
Novo Nordisk reported second-quarter adjusted sales of 78.49 billion Danish kroner, up 7% from a year earlier. Adjusted operating profit, a key metric for investors, increased 11% to 33.39 billion kroner, while net profit declined 21% to 20.99 billion kroner.
Although demand for Wegovy continues to support Novo Nordisk’s business, investors remain focused on pipeline performance and intensifying competition in the global weight-loss drug market.
